Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd. Janik JE, et al. Among authors: gause bl. J Natl Cancer Inst. 1996 Jan 3;88(1):44-9. doi: 10.1093/jnci/88.1.44. J Natl Cancer Inst. 1996. PMID: 8847725 Clinical Trial.
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL. Fenton RG, et al. Among authors: gause bl. J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74. doi: 10.1097/00002371-199609000-00006. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8941876 Clinical Trial.
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
Miller LL, Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, Holmlund JT, Curti BD, Sznol M, Smith JW 2nd, Urba WJ, Donegan SE, Watson TM, Longo DL. Miller LL, et al. Among authors: gause bl. Blood. 1999 May 15;93(10):3250-8. Blood. 1999. PMID: 10233876 Free article. Clinical Trial.
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Janik JE, Miller LL, Korn EL, Stevens D, Curti BD, Smith JW 2nd, Sznol M, Conlon KC, Sharfman W, Urba WJ, Gause BL, Longo DL. Janik JE, et al. Among authors: gause bl. Blood. 2001 Apr 1;97(7):1942-6. doi: 10.1182/blood.v97.7.1942. Blood. 2001. PMID: 11264156 Free article. Clinical Trial.
34 results